Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder (PR Newswire via Yahoo! Finance)
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that its New Drug Application for oxybutynin chloride topical gel , has been accepted for filing by the U.S.

The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing (Business Wire via Yahoo! Finance)
PARSIPPANY, N.J.----The Medicines Company announced receipt of a not approvable letter from the U.S. Food and Drug Administration on a supplemental New Drug Application for an additional dosing regimen for Angiomax in the treatment of acute coronary syndromes initiated in the emergency department.

LDR Spine has received FDA clearance for a partial vertebral body replacement device, the (Medical Device Link)
Austin Business Journal reports. The ROI-T device has a shape that conforms to the anterior vertebral body. But it is thin and its end is tapered, so it can be implanted in a minimally invasive procedure. The company says more new product approvals should come by the end of the year.